International Journal of Engineering Research & Management Technology

ISSN: 2348-4039

April-2018 Volume 5, Issue-2

Email: editor@ijermt.org www.ijermt.org

STUDY ON THE REGISTRATION OF PHARMACEUTICAL DRUG PRODUCT IN EMERGING MARKET

Khambete Sangeeta Dattatraya

Research Scholar ,Kalinga University

Naya Raipur, Chhattisgarh

Dr. Shilpi Shrivastava

Professor , Kalinga University

Naya Raipur, Chhattisgarh

Abstract

The registration of pharmaceutical drug products in emerging markets is the task that presents the greatest challenge. In nations that are regulated, the criteria for regulatory compliance are harmonized through the filing of common technical documents (CTDs), but the requirements in developing markets are more varied. Regulatory authorities and pharmaceutical industries from the came together at the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) to discuss various aspects of drug registration. However, there is no such harmonized guideline for emerging markets, with the exception of the Association of) and the Gulf Co-operation Council (GCC), where harmonization exists in clusters with their mutual agreements. The optimization and harmonization criteria have now become necessary, and they may be studied via the lens of the incidence of greater costs associated in the availability of pharmaceuticals, quality requirements of premise and research and development, and regional registration requirements. In the dossier registration process, the data on quality, safety, and efficacy are of significant relevance. In order to participate in the emerging market and contribute to the improvement of public health and safety, the pharmaceutical industry is required to comply with the regulatory requirements. In addition to this, the study provides a concise explanation of the various regulatory requirements for the registration of medicinal products in emerging markets, as well as comparative statistics for the registration of dossier applications in emerging markets.

Keywords: *Dossier Registration, Emerging Markets, Drug Product.*

INTRODUCTION

Drug Regulatory Affairs is the one that has been developing and expanding the most, and it is also the one that has been least affected throughout acquisitions and mergers, as well as the recession. The harmonisation of standards on a global scale has resulted in a more consistent approach to the reporting of regulatory information. The creation of any dossier for export registration requires the utilisation of the Systematic formulation development as its backbone. Because the registration requirements for many nations are distinct from one another, it is challenging for any business to create products that are suitable for every place, it is vital for us to take into account the vast majority of criteria when submitting technical data, as this will assist

in the process of export registration. As a result, harmonisation takes place, as clusters in emerging markets are required for the submission of dossiers, such as ASEAN. Harmonisation may be seen in countries like Thailand, Singapore, and Vietnam, amongst others.

Within the next ten years, projected to replace Europe as the largest pharmaceutical market, and sales are currently being driven by expansion in important emerging nations. For example, it is anticipated that China would overtake the United States as the largest market for pharmaceuticals by the year 2020.Because more than 85 percent of the population is concentrated in developing countries, these markets have been the primary drivers of economic expansion.

As many multinational corporations have relocated their headquarters to growing economies including China, India, Russia, Korea, Saudi Arabia, and Mexico. The expansion is gradually expanding beyond the use of CROs and the marketing of well-established goods to include early-stage research and technology that is focused at specific medical needs of patients in these countries. This shift is occurring at a rapid pace. Including the vast majority of patients from the relevant countries in clinical development programmes is one strategy to speed up the process of introducing new medications to emerging markets in a timely manner. The vast majority of pharmaceutical corporations regularly engage in this practise. These development programmes are responsible for increased life expectancy as well as changes in lifestyle that are made feasible as a result of accelerated economic expansion. The rise in importance of emerging markets and their expansion throughout the world has led to an increase in the demand for both general and essential medications. Cooperation on a regional level is necessary in order to ensure the proper development of scientific competence.

Aside from this, the capacity for regional manufacturing is the most anticipated means to promote economic growth, and defined quality standards should fulfil the requirements for worldwide export. The legislative and political aspects are the most important ones; nations need assistance to build efficient national laws, and they also need to cooperate with one another on a regional level in order to improve their access to necessary medications. Pharmaceutical companies and regulatory agencies are working together to improve the drug development process and the approval process. One example of this collaboration is the ICH guidelines for eCTD submission and QbD, which contribute to better first time product quality and shorten the review time required by regulatory agency. These guidelines are well accepted by regulated markets, and some countries of semi-regulated markets, like India and China, use the CTD format.

Through both its prequalification initiative and its other operations, the WHO has maintained its position as one of the most important organisations in terms of the development of scientific ability. Because the issue of pharmaceutical product quality is of such critical importance, the World Health Organisation (WHO) and other international organisations, such as the drug regulatory bodies of rich nations, should be encouraged and supported to extend their existing initiatives that provide assistance to poor countries. The regulatory authority for the pharmaceutical industry in the Middle East may be found in the Ministries of Health of the GCC nations They also regulate the prices of pharmaceutical products and bring about harmonisation of the various prices and the regulatory process. In May 1999, the GCC implemented a centralised system known as the Gulf Central Committee for Drug Registration (GCC-DR), which currently operates in parallel to the regulatory regimes that are in place throughout the region.

It is anticipated that the Latin American markets would expand at a healthy compound annual growth rate of 10%, from USD 37.6 billion in 2009 to USD 62 billion in 2012, as a result of improvements in regulatory

regulations and an expanding manufacturing base for generic medications by drug producers in the United States. These countries' robust economic growth will be the driving force behind the profitable expansion in these markets.

The regulation of health is considered to be one of the fundamental duties of public health. Effective regulation of medicines promotes and protects public health by ensuring the quality, safety, and efficacy of medicines; promoting the adequate manufacture, storage, and distribution of medicines; facilitating the fight against substandard, spurious, falsely-labeled, falsified, or counterfeit (SSFFC) medical products; providing the necessary information to health professionals and patients so that they can use medicines in a rational manner; and ensuring that access to medicines is not restricted. To this end, it is of the utmost importance to establish effective national regulatory agencies (through a national system that promotes access to health care and that protects its citizens against health risks) with a clear mission, realistic goals, skilled and trained workers, sustainable financing, access to up-to-date technical literature, and the capacity to adapt and respond to the ongoing and varying demands posed by the challenges faced by the countries. PAHO continues to support and develop different procedures and instruments to enhance the NRAs' regulatory and oversight responsibilities, in recognition of the vital role that NRAs serve and the need to increase their regulatory competence.

This is done in order to strengthen the NRAs' regulatory and oversight roles. For instance, the nations of the Region, together with the assistance of PAHO, began negotiations in Oaxaca, Mexico, on exchange and mutual recognition methods. This, in turn, led to the evaluation and identification of regional reference NRAs. Similarly, in 1999, the Governing Bodies of the Health Organisation suggested that the Pan for Drug Regulatory Harmonisation be formed in order to respond to the need for efforts that promote drug regulatory harmonisation in the. This was done in order to establish the Network for Drug Regulatory Harmonisation Within the framework of national and subregional health realities and policies, works to promote regulatory harmonisation procedures throughout the Americas. This is done while understanding existing imbalances in the system.

Pander's mission is to promote drug regulatory harmonisation, which includes aspects such as quality, safety, efficacy, and the rational use of pharmaceutical products, while strengthening the capabilities of the Region's NRAs. This mission is based on the population's right to have access to quality medicines that are in line with advances in science and technology. Pander was founded in 1998. PANDRH's goals consist of, among other things, bolstering the National Regulatory Authorities (NRAs) in the countries that make up the Region and promoting cooperation among them; preparing and approving technical documents on drug regulation; identifying mechanisms to support the implementation, monitoring, and evaluation of proposals adopted by NRAs; and promoting the establishment of reference standards. NRAs The Pan for Drug Regulatory Harmonisation consists of the Pan American Conference on Drug Regulatory Harmonisation, the Steering Committee, the technical working groups (for any areas selected as priority by the Conference and the Secretariat), and the Pan Organisation, which serves as the network's Secretariat. was established in order to ensure that drug regulations across the are consistent with one another. Since the Network was first founded, thirteen working groups (WGs) have been formed, and it is their job to make harmonised ideas on topics that are important and of interest in the field of pharmaceutical regulation. Seven conferences on the harmonisation of drug regulatory standards have been hosted so far. The first of these was held in Washington, District of Columbia, in the year 1997, and it was the catalyst that led to the formation.

At the Network's sixth conference, which was held in Brazil in 2011, and at subsequent meetings of PANDRH's Steering Committee, the National Reference Agencies of the Region requested that the Secretariat (PAHO) coordinate the preparation of a strategic development plan to tackle the unfinished agenda and new challenges This request was made in light of the needs of the countries of the Americas as well as the future challenges that PANDRH will likely face in the future. It was proposed that this plan be developed by an ad hoc group comprised of NRA representatives and observer members, and that it be based on the following components: the global situation; regulatory challenges; the pharmaceutical profile of the countries; the results of the evaluations of the NRAs; lessons learned from the work carried out to date the degree of implementation of the technical documents that were produced. It was also suggested that the plan should examine the impact that had on the NRAs in the region, establish the priorities for the Network for the years 2014–2020, examine the bylaws that are currently in place for the Network, suggest more effective communication and decision-making mechanisms for the Network, and propose a sustainable mechanism to strengthen regulatory training in the region.

OBJECTIVE

1. The study Registration of Pharmaceutical drug product in Emerging Market.
2. The study Emerging market and for betterment of public Health and safety.

RESEARCH METHODOLOGY

Countries that have established regulations to demonstrate the efficacy, safety, through clinical trials or Bioequivalence studies with the innovator's product in the drug approval process are included in the first category of the regulatory regime in LATAM countries. The second category is comprised of countries that do not have established regulations. There are other restrictions in place for the licencing of new or generic drugs in such nations as Argentina, Chile, Columbia, Ecuador, and Paraguay; however, these laws are not as rigorous as those in the first category. The nations that fall into the last group, which includes Guatemala, Barbados, Bolivia, Nicaragua, and Peru, have restrictions for the licencing of medications that are not fully developed. Although it mostly adheres to its own rules, the rest of the nations in the area insist on following ICH region for certain data such as stability and clinical trials. For example, the countries in the ASEAN region demand data according to the ASEAN CTD, which is identical to ICH CTD in terms of the data requirements organised in Parts. Table 1 provides a tabular breakdown of the CTD's essential sections as well as the primary needs for each location.

Table 1 Structure of Common Technical Document (CTD)

ICH CTD	ASEAN CTD	Description	Remarks
Module 1 Regional and Administrative Information	Part I	Contains documents that are specific to each region. Thismodule is not part of CTD. Basically consists of administrative documents like Application form, legal documents (GMP,Licenses etc.), labeling etc.	Required for generics and New Drug

Module 2 Overall Summary	Part II	This module summarizes the Module 3, 4 and 5. It includes Quality Overall summary, Non Clinical Overview and Summary and Clinical Overview and Summary. The summary provides reviewer the abstract of documents provided in the whole application	Required for generics and New Drug. For generics summary on Quality part only required
Module 3 Quality		The documents related to Chemistry, manufacturing and Control of both Drug Substance and Drug Product isincluded in this module.	Required for generics and New Drug
Module 4 Safety	Part III	Non Clinical Study Reports – Data on pharmacologic, pharmacokinetic, and toxicological evaluation of the pharmaceutical product is provided.	Not required for generics
Module 5 Efficacy	Part IV	Clinical Study Reports - A critical assessment of the clinical data and related reports is provided in thismodule.	Not required for generics except Bioequivalence study



Figure 1. Organization Of A-CTD And CTD

There is a distinction in the way that papers are laid out between the ICH CTD and the ACTD. Because ACTD does not feature common technical document overviews and summaries as CTD does, the papers in ACTD are titled as part-I to part-IV rather than This is due to the fact that there are five modules in ICH CTD, each of which is designated to Module-V. The remaining documents include product information, administrative documents, quality documents, nonclinical documents, and clinical documents. The approval of a medication in certain countries necessitates the submission of certain extra documentation; for example, do not require samples of the drug, although must. Samples of the drug must be sent in the. Another document that must be shown is a Certificate of Pharmaceutical Product (COPP), as well as a manufacturing licence, both of which are essential in all nations that fall within the ASEAN area. Another document, known as GMP (Good Manufacturing Practises), is considered to be a PIC.

DATA ANALYSIS

There has been an upsurge in discovery research for diseases that are more prevalent in than they are in the as a result of the rising emphasis on the timely launch of life-saving medications for diseases in.

Chemistry, Manufacturing & control documents

API DMF Open part – Following data should be available in Open Part

- Nomenclature.
- General Properties.
- The name of the manufacturer and the location where the product was made.
- A condensed version of the flow diagram for the route of synthesis.
- Structural Elucidation.
- Impurities.
- Details on the methodology, including specifications
- Evaluation of the Container's Closure System
- Assessment of the Product's Stability Retest period & Storage
- Specification of the API, as well as the Method of Analysis and COA of the API Provided by the Applicant

Regulatory Filing Process

Figure 2. Dossier Application Filing For Generic Drug Product In Emerging Market

Manufacturing Process & Process Controls

- Specific details on the manufacturing process.
- The individual stages involved in the synthesis and purification of the API are discussed in detail.
- The particulars regarding the reagents, starting materials, intermediates, catalysts, and solvents that were used in the reaction.
- The type of apparatus, as well as its capacity and size.
- Specifications for in-process testing and quality control are provided.
- Both the master recipe and the batch production record are discussed.
- The process validation procedure has been provided (with a report of three batches of the same size and identical batch).

Packing Material

- Compatible storage, transit, and use should be possible with the material used for packaging.
- For primary packaging material, thorough specifications and methods of examination are necessary. This must also include identification for the materials used in construction.
- The standards for secondary packing material, as well as the technique of analysis, are necessary
- Printed materials for the packaging and PIL samples, as well as coloured artworks if available A Certificate of Analysis and a documentation of the Batch Packaging must be provided.
- It is recommended that the infrared spectra of the polybags be supplied. (Determination of the component used in the building's construction)

- The polymer that will be used for the immediate container of the API product has to be evaluated, identified, and characterised in accordance with the requirements outlined in the Pharmacopeia's General Monographs.

Initiation of harmonization in ASEAN

- An analysis showed that the absence of harmonisation in countries with rising markets led to needless duplication of effort, the waste of important resources, and an eventual increase in drug lag. This was the conclusion reached as a result of the findings. In 1967, the Association of was the organisation that took the first step towards harmonisation. The harmonisation had been taking place in groups, such as ASEAN and the Gulf Countries, but this aspect has to be revised once it has been translated. The format for the marketing application is quite similar to the format for the EU submission. There are a few nations, such as India, Ukraine, Russia, and South Africa, as well as those countries that have recently been harmonised, that use the format that is virtually identical to the EU-CTD standard. Therefore, their forms are brought into concordance with one another. The elimination of hurdles that hampered commerce in pharmaceuticals between member nations was facilitated by the process of harmonisation with GMP standards.
- As a result of their membership in the Association of and the Gulf Co-operation Council (GCC), the nations of the and Gulf regions have nearly completed the process of harmonising the regulatory environment in which they operate. On the other hand, the nations of the other regions have not yet completed the process of harmonising the regulatory environment in which they operate.

Effect of ASEAN harmonization of guidelines on pharmaceutical market

The harmonisation of regulatory norms across nations has a significant influence, not only on the market for pharmaceuticals but also on the approval of new drugs. The harmonisation of the process for the approval and registration of drugs has a beneficial impact on the pharmaceutical market in the nations in this group. The use of the CTD format for the registration of drugs has resulted in an increase in overall commerce among nations, giving them a strong position on the international stage.



Figure 3. ASEAN GDP From 1990-2020

CONCLUSION

In order to determine the degree of variation between the regulatory requirements of the various nations, a comparison has been made against the registration criteria for a variety of distinct groups of rising countries.

Before developing pharmaceuticals, it is essential for manufacturers, and notably generic businesses, to thoroughly evaluate the market interest, cost of development, target areas, and regulatory requirements. This is due to the fact that drug approval procedures throughout the world vary. It is not feasible to gain worldwide market harmonisation and approval at the same time, and it is much more difficult to launch in all of the areas at the same time. This is because of the diverse regulatory environments. As a result, it is vital to comprehend and develop the precise regulatory strategy by taking into consideration the target locations, the various patent periods and their extension, the numerous application options, the data needs, and the deadlines for releasing goods to be marketed in different regions. This results in the elimination of studies that are not essential, a minimization of the delay in medication approvals, and a consequent reduction in the overall cost of research and development. The export market necessitates the generation of high-quality dossiers, which may be accomplished via the use of methodical Formulation Development and an awareness of the regulations of each individual nation. The preparation of a high-quality dossier and effective responses to questions from regulatory bodies will both benefit from careful planning and thorough execution during the formulation process.

REFERENCES

1. Badjatya JK, Bodla R. Drug product registration in semiregulated market. International Journal of Drug Regulatory Affairs [Internet]. 2018 Feb 06 [cited 2019 Aug 06]; 1(2):1-6. Available from: https://ijdra.com/index.php/journal/article/view/3
2. Tripathy S, Murthy PN, Patra BP. Integrating PLCM strategy in Pharmaceutical Emerging Market. International Journal of Drug Regulatory Affairs [Internet]. 2018 Dec 15 [cited 2019 Jul 15]; 6(4):21-32.
3. Badjatya J, Bodla R. Overview of Registration Requirements for Pharmaceuticals in Emerging Market. Journal of drug delivery and therapeutics [Internet]. 2013 Mar 02 [cited 2019 Jul 24]; 3(2): 227-232.
4. Alistair Davidson, Senior Director, Regulatory Delivery Solutions, Regulatory Strategy for the Emerging Markets –Far East, Africa, Middle East, Latin America [Internet]. ppdi; 2019 [cited 2019 Jul 21].
5. ICH. The Common Technical Document [Internet]. ICH; 2019 [cited 2019 Jul 26].
6. ICH M4S Guideline: Nonclinical Overview and Nonclinical Summaries of Module 2 and Module 4: Safety (R2) [Internet]. ICH; 2002 Dec [cited 2019 Jul 22
7. ICH. The eCommon Technical Document [Internet]. ICH; 2019 [cited 2019 Jul 12].
8. ICH .Q3B Guideline Impurities in New Drug Products Q3 (R2) [Internet]. ICH; 2006 Jun [cited 2019 Jul 22].
9. ICH .Q3A Guideline Impurities in New Drug Products Q3A (R2) [Internet]. ICH; 2006 Jun [cited 2019 Jul 24]. Available from: . ICH. Q2 (R1) Validation of Analytical Procedure Q2 (R1) [Internet]. ICH; 2005 Nov [cited 2019 Jun 08].
10. EMA. Guideline on excipients in dossier for application of marketing authorization of medical products [Internet]. EMA; 2007 Jun [cited 2019 Jun 12
11. ICH. Q6A. Specifications test procedure and acceptance criteria for new drug substance and new drug products (chemical substances) [Internet]. ICH; 1996 Oct [cited 2019 May 27].
12. ICH .Q1A (R2). Guideline Stability testing in New Drug Substance and New Drug Products Q1A (R2) [Internet]. ICH; 2006 Jun [cited 2019 Jul 21].

13. ICH. E9. Guideline on statistical principal of clinical trial E9 [Internet]. ICH; 2006 Jun [cited 2019 Jul 16].
14. ICH. S3A Guideline on toxicokinetics S3 (A) [Internet]. ICH; 2006 June [cited 2019 July 26].
15. Patel D, Badjatya JK, Patel A. Preparation and Review of Chemistry, Manufacturing and Control (CMC) Sections of CTD Dossier for Marketing Authorization. International Journal of Drug Regulatory Affairs [Internet]. 2017 Jun 08 [cited 2019 Aug 01]; 5(2):1-12.